Short Courses and Special Courses

SC30 - Diagnosis of Renal Neoplasms Using Integrated Histologic, Cytologic and Molecular Approaches in the Era of Precision Medicine

Friday, March 23, 2018 - 1:00 pm - 4:30 pm
This Short Course session includes up to a 30-minute break.

Session Credits:

3 CME and 3 SAMs


Christopher Przybycin, MD, and Jordan Reynolds, MD, Cleveland Clinic, Cleveland, OH
Jordan Reynolds, MD, Cleveland Clinic, Cleveland, OH
Ming Zhou, MD, PhD, University of Texas Southwestern Medical Center, Dallas, TX

Course Description

Diagnosis and classification of renal tumors have undergone tremendous changes in the last decade. Many new entities have been discovered. The molecular mechanisms of many tumors have been unraveled and consequently many new biomarkers and molecular tests have been increasingly used in the diagnosis and prognotification of renal tumors. Targeted therapy is available for many specific subtypes of renal tumors. All these changes were included in the new World Health Organization Classification of Renal Neoplasia, published in 2016. It is imperative for practicing pathologists to keep abreast with the "new" tumor entities, diagnostic criteria, diagnostic markers and tests, and recent changes to the grading and staging criteria for renal cell carcinomas. Rather than a rote list of tumors with characteristics, this practically oriented course will use cases that speakers collected from their daily sign-out to provide a pattern-based diagnostic approach that incorporates both "old" diagnostic entities and newly described entities that are important to recognize. When applicable, we will also provide ancillary testing methods including immunohistochemistry and molecular testing important for the work-up of renal tumors. This course is designed for advanced residents, fellows and general pathologists, as well as subspecialists in urological pathology.

Learning Objectives

Upon completion of this educational activity, the learner will be able to:

  • Recognize newly described renal tumor entities in renal neoplasia
  • Understand the molecular genetics of renal tumors that is most relevant to their clinical practice
  • Use pattern-based approach to the diagnosis of renal tumors, including new and old entities
  • Use immunohistochemistry in the work-up of difficult renal tumors
  • Be aware of important changes to the reporting RCC, including grading and staging
  • Understand the approach to work-up of needle biopsy of renal tumors.


Continuing Medical Education and Maintenance of Certification

The United States and Canadian Academy of Pathology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The United States and Canadian Academy of Pathology designates this live activity for a maximum of 3 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The USCAP is approved by the American Board of Pathology (ABP) to offer Self-Assessment credits (SAMs) for the purpose of meeting the ABP requirements for Maintenance of Certification (MOC). Physicians must take and pass the post-test in order to claim SAMs credit.

Physicians can earn a maximum of 3 SAM credit hours.


Return to 2018 Annual Meeting Short Course Page


view more